not like a bunch of 'on margin' sissies trying to avoid getting a real job....lololololol
Oct 6, 2014 FROST PHILLIP MD ET AL
10,000 Indirect Purchase at $8.36 - $8.37 per share. 84,0002
Oct 3, 2014 FROST PHILLIP MD ET AL
29,400 Indirect Purchase at $8.36 - $8.53 per share. 248,0002
Oct 2, 2014 FROST PHILLIP MD ET AL
35,000 Indirect Purchase at $8.25 - $8.36 per share. 291,0002
Oct 1, 2014 FROST PHILLIP MD ET AL
40,000 Indirect Purchase at $8.32 - $8.51 per share. 337,0002
2015 OPK doubles from today...betcha...
even moe' moola....$$$$$$$$...3 is going blow away earnings!
of course, ya think I'm here to twiddle.....lolol
Amateurs that made a decision to 'short' OPK feel compelled to show up on Yahoo to perpetually run their yaps, just roll with your choice to short and #$%$ about it,
based on the past performance of Dr. Frost, his savvy understanding of how to build it, market it, sell it!...what have you done Bozo???
shorts can invest as they wish, but drop the "stupid act', if possible.....lolol
Douglas W. House, SA News Ed...
•OPKO Health's (NYSE:OPK) oral vitamin D prohormone treatment Rayaldee achieves its primary endpoints in a 216-patient 38-site Phase 3 clinical trial evaluating its safety and efficacy as a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
•Rayaldee corrected vitamin D insufficiency in 96% of the patients in its cohort compared to 8% for placebo.
•The primary efficacy endpoint was a responder analysis where a responder was defined as a patient who demonstrated an average 30% decrease in plasma parathyroid hormone from pre-treatment baseline during the six-week treatment period. The specific proportion of responders and whether it was statistically significant is not disclosed, however.
•The company expects to submit its NDA by the end of 2014.
even Moe' $$$$$$